We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-26.25%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$455M
AUM Growth
-$327M
Cap. Flow
-$168M
Cap. Flow %
-36.97%
Top 10 Hldgs %
79.01%
Holding
161
New
35
Increased
35
Reduced
40
Closed
40

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$28.9M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$5.02M
3
ESPR
Esperion Therapeutics
ESPR
+$1.86M
4
RSLS
ReShape Lifesciences Inc. Common Stock
RSLS
+$1.72M
5
LFWD icon
ReWalk Robotics
LFWD
+$1.65M

Top Sells

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$8.71M
2
XERS icon
Xeris Biopharma Holdings
XERS
+$5.7M
3
FOLD
Amicus Therapeutics
FOLD
+$1.87M
4
APTX
Aptinyx Inc. Common Stock
APTX
+$1.19M
5
VKTX icon
Viking Therapeutics
VKTX
+$1.09M

Sector Composition

Rank Sector Weight
1 Healthcare 21.24%
2 Technology 0.34%
3 Consumer Staples 0.21%
4 Financials 0.17%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VIRX
76
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$166K 0.04%
11,433
+3,485
+44% +$142K
MBOT icon
77
Microbot Medical
MBOT
$113M
$150K 0.03%
87,243
+32,725
+60% +$124K
ALT icon
78
PUT
Altimmune
ALT
$581M
$139K 0.03%
+673
New +$2.38K
TENX icon
79
Tenax Therapeutics
TENX
$419M
$131K 0.03%
+68
New +$374K
LMFA
80
DELISTED
LM Funding America
LMFA
$117K 0.03%
+132
New +$239K
NUWE icon
81
Nuwellis
NUWE
$178K
– –
0
– –
TRAW icon
82
Traws Pharma
TRAW
$7.81M
$101K 0.02%
+127
New +$216K
CHEKZ
83
DELISTED
Check-Cap Ltd. Series C Warrant
CHEKZ
$101K 0.02%
252,155
-54,723
-18% -$31.7K
CVM icon
84
CEL-SCI Corp
CVM
$21M
$93K 0.02%
1,075
+248
+30% +$23.9K
NSPR icon
85
InspireMD
NSPR
$32.1M
$89K 0.02%
747
-681
-48% -$108K
SNES icon
86
SenesTech
SNES
$7.11M
$86K 0.02%
3
-17
-85% -$582K
QNRX
87
Quoin Pharmaceuticals
QNRX
$8.44M
– –
-1
Closed -$423K
MRNS
88
CALL
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$82K 0.02%
72
-327
-82% -$6.62K
VKTX icon
89
CALL
Viking Therapeutics
VKTX
$3.93B
$77K 0.02%
100
-440
-81% -$5.26K
SGLBW
90
DELISTED
Sigma Labs, Inc. Warrant
SGLBW
$74K 0.02%
188,813
-91,716
-33% -$35.8K
PRSO icon
91
Peraso
PRSO
$10.1M
$66K 0.01%
+498
New +$92.7K
DRRX
92
DELISTED
DURECT Corp
DRRX
$64K 0.01%
13,190
– –
FCSC
93
DELISTED
Fibrocell Science Inc.
FCSC
$64K 0.01%
+42,400
New +$84.8K
SGYPW
94
CALL
DELISTED
Synergy Pharmaceuticals, Inc. - Warrants
SGYPW
$59K 0.01%
5,382
– –
BIOC
95
DELISTED
Biocept, Inc.
BIOC
$49K 0.01%
192
-283
-60% -$142K
MNKD icon
96
CALL
MannKind Corp
MNKD
$1.21B
$48K 0.01%
+449
New +$762
VIRX
97
CALL
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$47K 0.01%
33
+6
+22% +$245
CRMD icon
98
PUT
CorMedix
CRMD
$577M
$41K 0.01%
61
+4
+7% +$27
CRMD icon
99
CorMedix
CRMD
$577M
$40K 0.01%
+6,132
New +$41K
MBAI
100
Check-Cap
MBAI
$8.12M
$37K 0.01%
849
-3,690
-81% -$248K
2 3
4
5 6

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2018 Portfolio in Review

As of Q4 2018, Sabby Management held 161 positions worth $455M, down 42% from $782M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Sabby Management withdrew a net $168M in Q4 2018, closing 40 positions and reducing 40 holdings. Its most notable exit was Amicus Therapeutics, an estimated $1.87M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 15% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Sabby Management opened a new position in State Street SPDR S&P Biotech ETF worth $4.47M.

  • Sabby Management's largest Q4 2018 buy was State Street SPDR S&P Biotech ETF: 62,266 shares worth $4.47M.
  • Sabby Management added most to Biogen in Q4 2018, an estimated $28.9M increase.
  • Sabby Management's biggest Q4 2018 reduction was Nektar Therapeutics, cutting an estimated $8.71M.
  • Sabby Management fully exited Amicus Therapeutics in Q4 2018, selling an estimated $1.87M.
  • Sabby Management's ten largest holdings make up 79% of its $455M portfolio in Q4 2018.
  • Sabby Management opened 35 new positions and closed 40 in Q4 2018.
  • Sabby Management's portfolio value fell 42% quarter-over-quarter to $455M.

Based on Sabby Management's 13F filing for Q4 2018, filed 14 Feb 2019.